Reduced Fidaxomicin Susceptibility May Emerge During C. Difficile Treatment, Study Finds

Healio (3/31, Stulpin) reported a study found that “clostridioides difficile isolates with reduced fidaxomicin susceptibility may emerge during treatment and could spread to other patients.” Researchers found that “of 108 patients treated with fidaxomicin, six had isolates with reduced fidaxomicin susceptibility three achieved clinical cure with fidaxomicin, two had clinical failure and one refractory CDI.” In addition, they “noted that none of the isolates with reduced susceptibility had mutations associated with rifamycin resistance and that all were susceptible to vancomycin, rifampin, moxifloxacin and erythromycin.” Researchers concluded, “Clinicians should be aware that reduced susceptibility should be considered as a potential contributor to fidaxomicin treatment failure.” The study was published in Clinical Infectious Diseases.